Endometrial Serous Adenocarcinoma

subtype

Identifier: CI-CAN-00005168
Entity page: /cancer/endometrial-serous-adenocarcinoma ↗
Edges: 87

Neighbours: 1 genes1 variants16 drugs10 trials
Drawn: 28 of 28 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,149 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Endometrial Serous Adenocarcinoma predicts response to …PREDICTS_RESPONSE_TO1 of 1
in context · predicts response to	ERBB2 Amplificationamplification → predicts response to Trastuzumab	sensitivity	C	Endometrial Serous Adenocarcinoma	1	Curated	civic	graph →
Endometrial Serous Adenocarcinoma …

Endometrial Serous Adenocarcinoma associated with …ASSOCIATED_WITH2 of 2
← associated with	ERBB2	supports	B	Endometrial Serous Adenocarcinoma	1	Curated	civic	graph →
← associated with	ERBB2	supports	C	Endometrial Serous Adenocarcinoma	1	Curated	civic	graph →

Endometrial Serous Adenocarcinoma associated with …ASSOCIATED_WITH2 of 2

← associated with

ERBB2

supports

Endometrial Serous Adenocarcinoma investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 31show all (up to 200)
→ investigated in trials for	Paclitaxelsmall molecule 13 trials (3 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Carboplatinsmall molecule 10 trials (3 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Cisplatinsmall molecule 8 trials (0 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Bevacizumabmonoclonal antibody 7 trials (3 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	7	Observed	clinicaltrials	graph →
→ investigated in trials for	Doxorubicinsmall molecule 3 trials (0 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Cediranibsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Filgrastimother 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Metforminsmall molecule 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Mirvetuximab Soravtansineadc 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Niraparibsmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Pegfilgrastimother 2 trials (0 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumabmonoclonal antibody 2 trials (2 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Temsirolimussmall molecule 2 trials (1 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Adavosertibsmall molecule 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Akt Inhibitor MK2206 1 trials (0 active) · roll-up of the cancer and its descendants	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →

Endometrial Serous Adenocarcinoma studied in …STUDIED_INderived10 of 51show all (up to 200)
→ studied in	NCT05256225Phase 3 · recruiting Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma · condition mapped ONTOLOGY_EXACT · 51 trials mapped (16 active)	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00977574Phase 2 · active not recruiting Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 51 trials mapped (16 active)	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · condition mapped ONTOLOGY_EXACT · 51 trials mapped (16 active)	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03660826Phase 2 · active not recruiting Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone · condition mapped ONTOLOGY_EXACT · 51 trials mapped (16 active)	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06792552Phase 1 · recruiting A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors · condition mapped ALIAS · 51 trials mapped (16 active)	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05231122Phase 2 · recruiting Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer · condition mapped CURATED_BROADER · 51 trials mapped (16 active)	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03914612Phase 3 · active not recruiting Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer · condition mapped ONTOLOGY_EXACT · 51 trials mapped (16 active)	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03120624Phase 1 · active not recruiting VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer · condition mapped CURATED_BROADER · 51 trials mapped (16 active)	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06476808Phase 1 · recruiting A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors. · condition mapped ALIAS · 51 trials mapped (16 active)	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04719273Phase 2 · completed Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer · condition mapped CURATED_BROADER · 51 trials mapped (16 active)	—	—	Endometrial Serous Adenocarcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains